AZD 5718

Drug Profile

AZD 5718

Alternative Names: AZD5718

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cardiovascular disorders; Coronary artery disease

Most Recent Events

  • 26 Aug 2017 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Coronary artery disease presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2017)
  • 01 Mar 2017 AstraZeneca completes a phase I trial for Coronary artery disease (In volunteers) in United Kingdom (PO, Suspension and Immediate release tablets) (NCT02963116)
  • 20 Dec 2016 Phase-I clinical trials in Coronary artery disease (In volunteers) in United Kingdom (PO, Suspension, Immediate release tablets) (NCT02963116)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top